In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Treatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...

The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 ...

A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...

Nck modulator reduced evidence of inflammation in an animal model of dermal irritationCompelling preclinical data support continued development ...